CA2428837A1 - Microspheres of pancreatic enzymes with high stability - Google Patents
Microspheres of pancreatic enzymes with high stability Download PDFInfo
- Publication number
- CA2428837A1 CA2428837A1 CA002428837A CA2428837A CA2428837A1 CA 2428837 A1 CA2428837 A1 CA 2428837A1 CA 002428837 A CA002428837 A CA 002428837A CA 2428837 A CA2428837 A CA 2428837A CA 2428837 A1 CA2428837 A1 CA 2428837A1
- Authority
- CA
- Canada
- Prior art keywords
- microspheres
- hydrophilic polymer
- mixture
- process according
- title
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
- C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
- C12N11/082—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
- C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
Abstract
The present invention refers to new microspheres including pancreatic enzymes, pharmaceutical compositions containing them, and a process to obtain them. The process here described doesn't involve the use of solvents and proves to be remarkably shorter and efficient than the producing methods of the prior arts. The microspheres obtained, including one or more pancreatic enzymes, one or more hydrophilic low-melting polymers and eventual excipients, have an high enzymatic activity, bio-availability and stability.
Description
MICROSPHERES OF PANCREATIC ENZYMES WITH HIGH STABILITY AND
PRODUCTION METHOD THEREOF
>=IELD OF' THE INVENTION
The present invention refers to the production of microparticles for pharmaceutical s use. Microspheres including pancreatic enzymes in stabilized form are described, with high bio-availability and high enzymatic activity. It is moreover described the production process of said microspheres through a high-energy granulation and spheronisation process,~without the presence of solvents.
PRIOR ART .
so A reduced exogenous production of enzymes by the pancreatic gland can be due to different pathologic conditions. The unsuccessful or insufficient production of di-gestive enzymes in particular is due to the mucoviscidosis (cystic fibrosis), to ob-structions of the common bile duct, to pancreatic carcinoma and to pancreas in-flammatory states (chronic pancreatitis). As a consequence the persons affected 15 , with these pathologies become unable to digest the foods by decomposing them into molecules absorbable by the gastrointestinal tract.
The disease brings to loss of weight and can have deadly outcome. The therapy consists of substitute oral administration of pancreatic enzymes of animal origin (here called "pancreatin" for the sake of brevity). The pancreatin is formed for the 2 o most part by lipase, amylase and protease; mainly the lipase catalyses the hy drolysis of the fats into fatty acids and glycerol, the amylase metabolizes the starch into dextrins and sugars and the protease decomposes the proteins into peptides and amino acids (G. J. Peschke, Pancreatic enzymes (Pancreatin), in Topics in pharmaceutical sciences, D. D. Breimer, D. J. A. Crommelin, K. K.
25 Midha, Federation Internationale Pharmaceutique (FIP), The Hague, 1989).
The pancreatin is extracted, preferably but not only, from the pig pancreas:
The pharmaceutical most suitable and effective form for pancreatin is that of spheres or pellets or minitablets. In case of oral administration, these formulations are provided with gastroresistant coatings: this is necessary by the fact that the 3 o pancreatic enzymes are inactivated by the acid pH of the stomach and must be delivered just when in contact with the duodenal pH.
The administration of small-sized multiparticles forms is particularly important to ensure a proper distribution of the enzymes in the food during the gastric transit and a remarkable delivery rate when the microspheres reach the duodenal pH. To improve the food digestion, it is particularly important that the microsphere are small sized, so that the enzymes are delivered onto a wide surface area and have a fast gastric transit.. To this purpose Meyer has demonstrated that spheres of 1 mm passed through the stomach with times significanfily shorter than spheres .of. 2 or 3 mm diameter (J. 'H. Meyer, J. Elashoff, V. Porter-Fink, J. Dressman, G.
L.
Amidon, Gastroenterology, 94, 1315, 1988).
Pancreatin is an enzyme with particular stability problems: it is in fact been noticed Z o its inactivation, partial or total, in case of long exposure to water environmenfi or heating at high temperature, or for simple storage at high temperature (G. J.
Pescke, Pancreatic Enzymes (Pancreatin) ch. 10, p. 133). The most unstable among fihe pancreatic enzymes proves to be the lipase, which is also the most im-portant enzyme in the substitute therapies. In tests made by the Applicant the s5 pancreatin, preserved for 7 days at 40°C at 75% relative humidity, loses 45% to 60% of enzymatic activity (lipase).
The pancreatin lability problems have influenced all the production processes of microparticles of said enzyme, reducing the range of the micronisation processes applicable to this product.
2 o M. Buu describes (patent TW-A-310277) the preparation of an extrudate product obtained through water granulation, desiccation, re-granulation, extrusion and following selection. JP-A-08109126 claims a production method based on the ap-plication in fluid bed of pancreatin powder on sugar spheres through the simulta-neous atomisation of a water solution containing a ligant (hydroxypropylcellulose).
25 An analogous method is described in EP-A-277741, where it is described the use of LHPC (low viscosity hydroxypropylcellulose) in water solution to apply pow-dered pancreatin on inert nuclei (Nonpareil seeds). All these methods involve the contact of pancreatin with water andlor other solvents in dynamic conditions of particles mixing; as also highlighted in the experimental part of the present appli-3 o cation, the wet granulation leads to a partial denaturation of pancreatin, with the.
formation of granules less active than the native enzyme.
An example of preparation of pancreatin pellets without use of solvents is de-scribed by Faassen and Vromans in WO-A-9638169: pancreatin is compressed by means of a roll compactor and then shelled to obtain irregularly-shaped pellets.
Boedecker et al. have obtained regularly-shaped pellets through extrusion and following spheronisation: in their EP-A-583726 is described the production of pel-lets with sizes included between 0.7 and 1.4 mm. An extrusion process is used also in the patent JP-A-04187085, to obtain pellets with sizes 1.5 to 3 mm; as ex-trusion solvent is used water or a mixture of water and ethyl alcohol. Atzl et al.
(WO-A-9107948) use a process similar to wet granulation to obtain spherical parti-cles with sizes 0.3 to 4 mm. In DE-A-A3422619 minitablets are obtained with di-Zo ameter of 1-2.5 mm and height 1-2.5 mm through compression with suitably modi-fied punches. In DE-A-2923279, assigned to Fischer et al., pancreatin is extruded in presence of isopropyl alcohol or acetone, spheronized and finally desiccated.
The above mentioned extrusion processes give irregular surface particles which require further size homogenization processes, with consequent longer production time and greater enzyme inacfiivation risk. This goes to the detriment of the en-zyme stability and involves high industrial costs; moreover, as proved in the ex-perimental part, the extrusion processes in presence of solvent, presents serious problems of loss of enzymatic activity. In the light of the prior art, it lacks an effi-cient process, having an industrial low cost, giving a very fine pellet size without 2 o causing denaturation and loss of enzymatic activity; moreover are not yet available pancreatin microspheres with reduced size and high enzymatic activity.
SUMMARY
The present invention refers to new microspheres including pancreatic enzymes, pharmaceutical compositions containing them, and a process to obtain them. The process here described does not involve the use of solvents and proves to be re markably shorter and efficient than the prior art methods. The obtained micro-spheres, including one or more pancreatic enzymes, one or more hydrophilic low-melting polymers and eventual excipients, have a high enzymatic activity, bio-availability and stability.
3 o FIGURES DESCRIPTION .
Figures 1A and 1 B: Course of the enzymatic title (lipase) of microsphere produced according to the present invention, during 6 months period.
PRODUCTION METHOD THEREOF
>=IELD OF' THE INVENTION
The present invention refers to the production of microparticles for pharmaceutical s use. Microspheres including pancreatic enzymes in stabilized form are described, with high bio-availability and high enzymatic activity. It is moreover described the production process of said microspheres through a high-energy granulation and spheronisation process,~without the presence of solvents.
PRIOR ART .
so A reduced exogenous production of enzymes by the pancreatic gland can be due to different pathologic conditions. The unsuccessful or insufficient production of di-gestive enzymes in particular is due to the mucoviscidosis (cystic fibrosis), to ob-structions of the common bile duct, to pancreatic carcinoma and to pancreas in-flammatory states (chronic pancreatitis). As a consequence the persons affected 15 , with these pathologies become unable to digest the foods by decomposing them into molecules absorbable by the gastrointestinal tract.
The disease brings to loss of weight and can have deadly outcome. The therapy consists of substitute oral administration of pancreatic enzymes of animal origin (here called "pancreatin" for the sake of brevity). The pancreatin is formed for the 2 o most part by lipase, amylase and protease; mainly the lipase catalyses the hy drolysis of the fats into fatty acids and glycerol, the amylase metabolizes the starch into dextrins and sugars and the protease decomposes the proteins into peptides and amino acids (G. J. Peschke, Pancreatic enzymes (Pancreatin), in Topics in pharmaceutical sciences, D. D. Breimer, D. J. A. Crommelin, K. K.
25 Midha, Federation Internationale Pharmaceutique (FIP), The Hague, 1989).
The pancreatin is extracted, preferably but not only, from the pig pancreas:
The pharmaceutical most suitable and effective form for pancreatin is that of spheres or pellets or minitablets. In case of oral administration, these formulations are provided with gastroresistant coatings: this is necessary by the fact that the 3 o pancreatic enzymes are inactivated by the acid pH of the stomach and must be delivered just when in contact with the duodenal pH.
The administration of small-sized multiparticles forms is particularly important to ensure a proper distribution of the enzymes in the food during the gastric transit and a remarkable delivery rate when the microspheres reach the duodenal pH. To improve the food digestion, it is particularly important that the microsphere are small sized, so that the enzymes are delivered onto a wide surface area and have a fast gastric transit.. To this purpose Meyer has demonstrated that spheres of 1 mm passed through the stomach with times significanfily shorter than spheres .of. 2 or 3 mm diameter (J. 'H. Meyer, J. Elashoff, V. Porter-Fink, J. Dressman, G.
L.
Amidon, Gastroenterology, 94, 1315, 1988).
Pancreatin is an enzyme with particular stability problems: it is in fact been noticed Z o its inactivation, partial or total, in case of long exposure to water environmenfi or heating at high temperature, or for simple storage at high temperature (G. J.
Pescke, Pancreatic Enzymes (Pancreatin) ch. 10, p. 133). The most unstable among fihe pancreatic enzymes proves to be the lipase, which is also the most im-portant enzyme in the substitute therapies. In tests made by the Applicant the s5 pancreatin, preserved for 7 days at 40°C at 75% relative humidity, loses 45% to 60% of enzymatic activity (lipase).
The pancreatin lability problems have influenced all the production processes of microparticles of said enzyme, reducing the range of the micronisation processes applicable to this product.
2 o M. Buu describes (patent TW-A-310277) the preparation of an extrudate product obtained through water granulation, desiccation, re-granulation, extrusion and following selection. JP-A-08109126 claims a production method based on the ap-plication in fluid bed of pancreatin powder on sugar spheres through the simulta-neous atomisation of a water solution containing a ligant (hydroxypropylcellulose).
25 An analogous method is described in EP-A-277741, where it is described the use of LHPC (low viscosity hydroxypropylcellulose) in water solution to apply pow-dered pancreatin on inert nuclei (Nonpareil seeds). All these methods involve the contact of pancreatin with water andlor other solvents in dynamic conditions of particles mixing; as also highlighted in the experimental part of the present appli-3 o cation, the wet granulation leads to a partial denaturation of pancreatin, with the.
formation of granules less active than the native enzyme.
An example of preparation of pancreatin pellets without use of solvents is de-scribed by Faassen and Vromans in WO-A-9638169: pancreatin is compressed by means of a roll compactor and then shelled to obtain irregularly-shaped pellets.
Boedecker et al. have obtained regularly-shaped pellets through extrusion and following spheronisation: in their EP-A-583726 is described the production of pel-lets with sizes included between 0.7 and 1.4 mm. An extrusion process is used also in the patent JP-A-04187085, to obtain pellets with sizes 1.5 to 3 mm; as ex-trusion solvent is used water or a mixture of water and ethyl alcohol. Atzl et al.
(WO-A-9107948) use a process similar to wet granulation to obtain spherical parti-cles with sizes 0.3 to 4 mm. In DE-A-A3422619 minitablets are obtained with di-Zo ameter of 1-2.5 mm and height 1-2.5 mm through compression with suitably modi-fied punches. In DE-A-2923279, assigned to Fischer et al., pancreatin is extruded in presence of isopropyl alcohol or acetone, spheronized and finally desiccated.
The above mentioned extrusion processes give irregular surface particles which require further size homogenization processes, with consequent longer production time and greater enzyme inacfiivation risk. This goes to the detriment of the en-zyme stability and involves high industrial costs; moreover, as proved in the ex-perimental part, the extrusion processes in presence of solvent, presents serious problems of loss of enzymatic activity. In the light of the prior art, it lacks an effi-cient process, having an industrial low cost, giving a very fine pellet size without 2 o causing denaturation and loss of enzymatic activity; moreover are not yet available pancreatin microspheres with reduced size and high enzymatic activity.
SUMMARY
The present invention refers to new microspheres including pancreatic enzymes, pharmaceutical compositions containing them, and a process to obtain them. The process here described does not involve the use of solvents and proves to be re markably shorter and efficient than the prior art methods. The obtained micro-spheres, including one or more pancreatic enzymes, one or more hydrophilic low-melting polymers and eventual excipients, have a high enzymatic activity, bio-availability and stability.
3 o FIGURES DESCRIPTION .
Figures 1A and 1 B: Course of the enzymatic title (lipase) of microsphere produced according to the present invention, during 6 months period.
DETAILED DESCRIPTION OF THE INVENTION
Object of the present invention is a process allowing to obtain microspheres of pancreatic enzymes having extremely reduced sizes'and a high and stable enzy-matic activity.
The process is characterized in that a solid mixture including one or more pancre-atic enzymes, one or more hydrophilic low-melting polymers and eventual excipi-ents, is heated at a .temperature equal or higher than the melting temperature of said hydrophilic low-melting polymer, under stirring.
The components of the mixture to be used in he process are described in detail Z o as follows.
With "pancreatic enzymes" is meant any one of the enzymes included in the pan-creatic secretion, such as amylase, lipase, protease, or their mixture in any pro-portion, .or any extract of pancreatic origin having enzymatic activity, such as pan-creatin.
15 Said enzymes can be indifferently obtained through extractive way from' the pan-creas, or produced artificially, for example through synthetic or recombinant way;
in the present process they are preferably used in form of powder. .
The hydrophilic low-melting polymer has melting point between 20°C
and 90°C, preferably between 30°C and 70°C. Examples of hydrophilic low-melting polymers 2 o are: polyethylene glycol (Lutrol E°, Sentry~ Carbonwax°), polyoxyethylene (Sen try~ Polyox~ WSR), copolymers of polyoxyethylene-polyoxypropylene (Lutrol F~).
The spheronisation mixture can include as well other excipients normally used in the pharmaceutical art, for example lubricants, glidants, coloring agents, diluents.
Among these last ones it can be mentioned lactose (anhydrous or hydrate), micro-25 crystalline cellulose (Avicel°, Emcocel°), calcium phosphate (Di Cafos~). In gen-eral, all the excipients which could improve or make more efficient the spheronisa-tion can be added to the composition The composition of the mixfiure subjected to the process object of the invention includes: pancreatic enzymes, in weight rate between 40% and 99%, preferably 3 o between 60% arid 85%, and hydrophilic polymers, between 1 % and 60%, pref .
erably between 15% and 40%.
The ratio between enzyme and hydrophilic low-melting polymer in the starting mixture is preferably between 4:1 and 1:1.
In the process object of the invention, the above described mixture is aggregated in micropellets and the micropellets are simultaneously subjected to a spheronisa tion process which regularise their surface. The process in question includes, in s particular, the following stages:
a: loading of a suitable reactor with said solid mixture or with its single compo-nents in solid state;
b: stirring of the mixture under high-energy condition and heating of the mixture at a temperature equal or higher than the melting temperature of said hydrophilic Zo. polymer;
c: cooling of the mixture under stirring condition;
d: recovery of the solidified microspheres. ' In case the mixture includes more hydrophilic tow-melting polymers, the mixture is heated at a temperature corresponding or higher than the melting temperature of 15 the polymer with the highest melting point.
A fundamental feature to obtain the microspheres with the here described proper-ties is to avoid the direct adding of any liquid to the solid mass. The process is then carried out in total absence of solvents, both watery or~organic, and avoiding any adding to the solid mass of polymers in melted state; it is then critical that all 2 o the mixture 'components are introduced into the reactor in the solid state before any heating is started.
The process is advantageously performed in a granulator-mixer or fluid bed. De-vices preferred for the performing of the process are the high-energy granulator-mixers, such as for example Zanchetta Roto, Diosna P, Niro Pellmix, Henschel, 2~ Robot Coupe RSI, Glatt VG, or the fluid beds provided with rotating disc such as for example the Glatt ones with Rotor insertion, the Aeromatic ones provided with rotating disc, the ICO PaG ones with insertion "tangential spray" and the Victor one series FL "rotary disc".
All these devices have in common that the mixture is subjected to a high-energy 3 o mixing action and is simultaneously heated at a temperature higher or equal to the melting one of the used hydrophilic polymer.
The stirring and heating action is performed for a total time (for instance 30'-75') sufficient to obtain the desired spheronisation degree. The temperature is then lowered to allow the microspheres to solidify; the mixing goes on, possibly with less energy, during the solidification stage (for instance for 10'-50'); the process ends with the interruption of the mixing and the recovery of the microspheres.
The whole process normally takes between 15' and 150', preferably between 50' and 100'.
The microspheres can be sieved through a vibrating sieve to reject eventual parti-cles out of the required size standards.
The so obtained microspheres, in particular the ones destined to the oral admini-1 o stration, are advantageously provided with a gastroresistant coating, (preferably non soluble at pH lower than 5.5), such to ensure the delivery of the active princi-ple just when the duodenum is reached, this way protecting it from the gastric pH;
the~application of said coating polymers is performed through spraying according to the prior art, in a fluid bed or in a spraying pan: coating is easy because of the spherical and regular surface of the microspheres. Examples of gastroresistant polymers which can be applied are: hydroxypropylmethylcellulose phthalate (for instance HP-50 or HP-55), hydroxypropylmethylcellulose acetate succinate (Aqoat°), acrylates (for instance Eudragit° L30D) polyvinylacetophthalate (Sure-teric~). To improve the applicability and the stability of the polymeric membranes 2 o formed by these polymers it can be added, mixed to the same coating, plasticizing agents such as for instance, triethylcitrate or dibutylphthalate. Moreover the gliding agents like the talc are helpful to reduce the adhesion among the pellets during the coating process.
The hydrophily of the above mentioned hydrophilic low-melting polymers allow the ' microspheres of the invention to quickly get the enzymes bio-available in the duo-denal environment, once the gastroresistant coating is dissolved.
A further object of the invention are microspheres of pancreatic enzymes with high bio-availability, produced according to the above described process.
The present process allows in fact to obtain new microspheres of pancreatic en-3 o zymes, having the following features: (a) reduced- size, with diameter between 10 pm and 1500 pm, preferably between 100 pm and 800 pm, thus with a high bio-availability of the enzyme once administered; (b) high enzyme title; with high en-zymatic title is meant an enzymatic title of the microsphere (measured in.
unit FIP/mg) equal to or higher than 90%, preferably equal to or higher than 95%, than the title of the solid mixture (enzyme, hydrophilic polymer and excipients in their initial quantities) from which they were produced; said mixture is in the following indicated as "physical mixture of their components". In other words, the activity of the pancreatic enzyme contained in the present microspheres is >_ 90%, preferably 95% of the activity of the native, untreated enzyme.
In case the microspheres include more than one pancreatic enzyme, the above mentioned enzymatic title is to be determined with reference to the activity of the so most thermolabile among them; for instance, in the case of pancreatin (which in-cludes lipase, amylase and protease), the enzyme whose title is measured is 1i-pase.
The microspheres according to the present invention have a high surface regular-ity and a prolonged stability of the enzymatic title in time.
z5 The microspheres obtained according the present invention include: one or more pancreatic enzymes, in weight ratio between 40% and 99%, preferably between 60% and 85%; one or more hydrophilic polymers, in quantity from 1 % to 60%, preferably between 15% and 40%, and excipients pharmaceutically acceptable.
A further object of the invention are pharmaceutical compositions including the 2o above described microspheres (eventually coated with coating polymers) and other excipients suitable for the pharmaceutical use, for example lubricants, gliding agents, coloring agents, diluents, etc. Said compositions can be formulated in forms suitable for the human or animal administration, for instance powders or pellets in sachets to dilute into water when used, suspensions, capsules of hard or 25 soft gelatine, tablets or microtablets.
The present invention offers several advantages: the direct spheronisation process is quick and inexpensive, since it is not necessary to use organic solvents, expen-sive and potentially dangerous if wasted in the environment, nor water, which re-quires long desiccation times and could inactivate the enzymes. Contrary to ali ex-3 o pectations, this process can be efficiently performed even at temperatures higher than the ones of said enzymes denaturation, without reducing the activity in fihe latter. The so produced microspheres have a very reduced diameter, lower than _$-700 Nm on average, thus allowing a high bio-availability. The microspheres' regu-lar surface allows to obtain pharmaceutical coated forms using a smaller quantity of coating polymers: this allows to reduce the quantity of coating agent and the time required for the coating, so reducing the process costs and the enzymes inac-tivation risks. As highlighted in the experimental part, the microspheres have an enzymatic title substantially unchanged as the native enzyme and a high activity persistence in storage condition, so allowing the production of pharmaceutical compositions of pancreatic enzymes with high activity and stability.
The present invention .is now described through the following not limitative exam-.~
z o pies.
EXPERIMENTAL PART
The production techniques of microspheres including pancreatic enzymes used as comparison with the present invention are: application of pancreatin on inert nu-cleus seed(ex. 1 ); extrusion and spheronisation (ex. 2). The process according to 15 the present invention (direct spheronisation) is performed in a fluid bed with rotat-ing disc (ex. 3), or with high-energy granulator-mixer (ex. 4). The enzymatic activ-ity is measured as lipasic activity: this enzyme has been chosen as reference since it is the most labile among the pancreatic enzymes. The activity is deter-mined according to analytical assays of biological type described in the European 2 o and American Pharmacopoeia and are expressed in Unit/mg (Unit F1P or Unit USP
according to the used assay). According to the European Pharmacopoeia 1 mg of pancreatin has to contain not less than 1 U-FIP of proteolitic activity, not less than 15 U-FIP of lipolitic activity and not less than 12 U-FIP of amilolitic activity.
Example 1 (Reference) 2 5 Preparation of pancreatin pellets through po~nrder application on inert nuclei In the basket of a fluid bed of the type Glatt GPCG-1 provided with rotor insertion (rotating disc) are placed 798.0 g of neutral pellets (type "non-pareil seeds", formed by saccharose and maize starch) having sizes between 250 and 350 pm.
The pellets are heated to 23°C by blowing warm air at 28°G.
The entering air 3o speed is 1.m/sec for.the process whole time. Separately the powdered pancreatin is mixed with 2.0% by weight of colloidal silica (Aerosil~ V200) to improve its flow-ability. The entering air temperature in the fluid bed is increased to 54°-C so that _g_ the pellets temperature is about 27-28°C, and 490.0 g of said mixture are applied through a proportioning device Heton Feeder at a rate of 26 g/min, while simulta-neously demineralized water is sprayed through a nozzle with a 0.8 mm hole and a flow rate of about 5-6 g/min. The filtering hoses are shaken for 5 secorids any 12 sec at the beginning of the process. After 25 minutes application it is necessary to shake the hoses for 5 sec any 6 sec. The pellets are dessicated by blowing air at 50°C, so to remove traces of residual water, and finally cooled by 30°C air for 10 minutes. The total time of the process is 120 minutes. This technique involves long process times since large amounts of active principle are brought into the filtering so hoses by the air stream; the size of the microspheres is difficult to control. The theoretical title of the pellets (lipase), calculated by the composition, was 18.27 U-USP/mg. The obtained lipase title was, on the contrary, 8.39 U-USP/mg: This technique involves a loss in the enzymatic activity equal to 54%.
Example 2 (Reference) i5 Preparation of pancreatin pellets through extrusion-saheronisation 660.0 g of pancreatin, 2465.1 g of Avicel° PH101 (microcrystalline cellulose), 165.0 g of Kollidon° K30 (polyvinylpyrrolidone) and 9.9 g of Syloid° 244 (colloidal silica) are mixed in an 18 liters mixing cube at 18 rpm.for 15 minutes. The mixture is fed through a co-rotating double screw extruder TSA EF 26-20. The cochlea of 2 o the feeding hopper is in position III, while the extruder cochlea is rotated at 125 rpm. Simultaneously a solution is fed including demineralized water and isopropyl alcohol in proportion 4:1 w/w by means of a peristaltic pump Watson-Marlow at about 20 g/min. The product is extruded with a 0.4 mm axial die. The total extru-sion time is 102 minutes. Immediately after the extrusion, the product is 25 spheronized with a spheronizer Glatt P-50 with rotating speed of 750 rpm .for 3 minutes. The so obtained pellets are desiccated in thermostatic furnace at 35 °C
for 15 hours. The theoretical title of the pellets, calculated by the composition, was 16.25 U-FIP/mg. The obtained .lipase title was, on the contrary, 0 U-FIP /mg.
It is supposed that the lipase is degraded (100% activity loss) because of the process 3o conditions (overheating of the product and/or presence of water in the extruded mass).
Further reference experiments made by the Applicant, did not highlight any better results: the wet granulation produces pellets with irregular surface requiring too high quantity of gastroresistant coating polymers; the application of pancreatin on pancreatin pellets (in fluid bed with rotating disc Glatt GPCG-1 with insertion Rotor "tangential spray") is a too long process, with frequent stoppage of the filter hoses, s and with difFiculty in controlling the microspheres sizes Example 3 Preparation of pancreatin pellefis through direct s,pheronisation in fluid bed 680.0 g of pancreatin and 320.0 g of PEG400 (polyethylene glycol) are placed in the basket of a fluid bed Glatt GPCG-1 provided with Rotor insertion. The disc is of so the knurled type and revolves at 1200 rpm, while simultaneously air is blown at 70°C at about 1-2 m/sec. The filter hoses are shaken for 5 sec any 6 sec. After 60 minutes spheronisation the entering air temperature is lowered to 20°C
to obtain the hardening of the pellets, while the disc rotation keeps on at 700 rpm. In this stage the shaking of the filters is of 5 sec any 12 sec. After about 30 min cooling s5 the product is unloaded from the basket of the fluid bed. The process total time is 90 minutes. The theoretical title of the pellets, calculated by the composition, was 40.12 U-FIP/mg. The obtained enzymatic title (lipase) was 38.12 U-FIP/mg, with.
an activity loss lower than 5%.
In all test the ponderal yield of pellets having sizes between 150 Nm and 700 Nm 2 o was measured (Table 1 ). With the same percentual compositions, by increasing the disc rotation speed, it was possible to reduce the spheronisation time, whereas the diameter of the microspheres did not change remarkably (Table 2).
Example 4 Precaration of pancreatin pellets through direct spheronisafiion in mixer-granulator 25 717.8 g of pancreatin and 190.8 of PEG4000 (polyethylene glycol) are placed in the tank of an high-energy mixer-granulator zanchetta Rotolab. The blades of the machine are run at 900 rpm and the heating jacket is set at 75°C. After 45 minutes spheronisation the heating is switched .off, the blades speed is lowered to 120 rpm and the jacket is cooled through pipe water flow. After 15 minutes cooling the pel-3 0 lets are unloaded. The process total time is 60 minutes. The theoretical title of the pellets, calculated by the composition, was 65.87 U-FIP/mg. The obtained enzy-matic title (lipase) was 67.80 U-FIP/mg.
Using the described process, with a mixer-granulator Zanchetta Rotolab P-50 spherical pellets are obtained which are afterwards coated with a gastroresistant membrane formed by HP-55, triethylcitrate and talc. The coated' pellets are wrapped up in thermo-sealed sachets (formed by a triple layer of paper, aluminum and polyethylene) and subjected to stability test at 25°C + 60% UR and at 30°C +
60% UR. The stability results of two lots made according to this process, ex pressed in percentage residual lipase activity, are reported in Figure 1: it is to no tice that the microsphere enzymatic activity remains substantially unchanged (fluctuating in a range of 90-110% of the initial value) during the whole test time (6 so months).
In short, the data of the above reported examples show that, while the known pro-cesses (reference examples 1-2) bring to a substantial reduction in the enzymatic activity, the process object of the present invention (examples 3-4) allows to obtain microspheres having very small sizes (<700 pm) and an enzymatic title 95% to 15 over 100% than the native enzyme, thus substantially unchanged; the stability in time of these values is confirmed by the data in figure 1. Said results then highlight the unforeseen efficiency of the process of the present invention and the better performance of the microspheres so obtained. Further tests have been made in the condition of the example 3, changing the hydrophilic low-melting polymer con-e o centration and the disc rotation speed. The table 1 and 2 show the process yield.
The PEG concentration is measured as weight rate of PEG with respect to the starting mixture; the process yield is calculated as weight rate (with respect to the starting mixture) of the microspheres fraction having dimensions included between 150 and 700 pm.
2 s Table 1.
ROTATION SPEED PROCESS YIELD
PEG % RPM WEIGHT % 150-700 M
20 700 48.9 25 700 58.1 30 700 80.6 32 700 91 ~8 Increasing the disc rotation speed to 1200 rpm (table 2) the yield values are not remarkably changed, while it has proved possible to reduce of 10-15% the process total time, to advantage of the enzyme stability.
Table 2.
ROTATION SPEED PROCESS YIELD
PEG % RPM WEIGHT % 150-700 M
20 1200 41.6 25 1200 47.9 30 1200 83.3 32 1200 . . ~ 90.8
Object of the present invention is a process allowing to obtain microspheres of pancreatic enzymes having extremely reduced sizes'and a high and stable enzy-matic activity.
The process is characterized in that a solid mixture including one or more pancre-atic enzymes, one or more hydrophilic low-melting polymers and eventual excipi-ents, is heated at a .temperature equal or higher than the melting temperature of said hydrophilic low-melting polymer, under stirring.
The components of the mixture to be used in he process are described in detail Z o as follows.
With "pancreatic enzymes" is meant any one of the enzymes included in the pan-creatic secretion, such as amylase, lipase, protease, or their mixture in any pro-portion, .or any extract of pancreatic origin having enzymatic activity, such as pan-creatin.
15 Said enzymes can be indifferently obtained through extractive way from' the pan-creas, or produced artificially, for example through synthetic or recombinant way;
in the present process they are preferably used in form of powder. .
The hydrophilic low-melting polymer has melting point between 20°C
and 90°C, preferably between 30°C and 70°C. Examples of hydrophilic low-melting polymers 2 o are: polyethylene glycol (Lutrol E°, Sentry~ Carbonwax°), polyoxyethylene (Sen try~ Polyox~ WSR), copolymers of polyoxyethylene-polyoxypropylene (Lutrol F~).
The spheronisation mixture can include as well other excipients normally used in the pharmaceutical art, for example lubricants, glidants, coloring agents, diluents.
Among these last ones it can be mentioned lactose (anhydrous or hydrate), micro-25 crystalline cellulose (Avicel°, Emcocel°), calcium phosphate (Di Cafos~). In gen-eral, all the excipients which could improve or make more efficient the spheronisa-tion can be added to the composition The composition of the mixfiure subjected to the process object of the invention includes: pancreatic enzymes, in weight rate between 40% and 99%, preferably 3 o between 60% arid 85%, and hydrophilic polymers, between 1 % and 60%, pref .
erably between 15% and 40%.
The ratio between enzyme and hydrophilic low-melting polymer in the starting mixture is preferably between 4:1 and 1:1.
In the process object of the invention, the above described mixture is aggregated in micropellets and the micropellets are simultaneously subjected to a spheronisa tion process which regularise their surface. The process in question includes, in s particular, the following stages:
a: loading of a suitable reactor with said solid mixture or with its single compo-nents in solid state;
b: stirring of the mixture under high-energy condition and heating of the mixture at a temperature equal or higher than the melting temperature of said hydrophilic Zo. polymer;
c: cooling of the mixture under stirring condition;
d: recovery of the solidified microspheres. ' In case the mixture includes more hydrophilic tow-melting polymers, the mixture is heated at a temperature corresponding or higher than the melting temperature of 15 the polymer with the highest melting point.
A fundamental feature to obtain the microspheres with the here described proper-ties is to avoid the direct adding of any liquid to the solid mass. The process is then carried out in total absence of solvents, both watery or~organic, and avoiding any adding to the solid mass of polymers in melted state; it is then critical that all 2 o the mixture 'components are introduced into the reactor in the solid state before any heating is started.
The process is advantageously performed in a granulator-mixer or fluid bed. De-vices preferred for the performing of the process are the high-energy granulator-mixers, such as for example Zanchetta Roto, Diosna P, Niro Pellmix, Henschel, 2~ Robot Coupe RSI, Glatt VG, or the fluid beds provided with rotating disc such as for example the Glatt ones with Rotor insertion, the Aeromatic ones provided with rotating disc, the ICO PaG ones with insertion "tangential spray" and the Victor one series FL "rotary disc".
All these devices have in common that the mixture is subjected to a high-energy 3 o mixing action and is simultaneously heated at a temperature higher or equal to the melting one of the used hydrophilic polymer.
The stirring and heating action is performed for a total time (for instance 30'-75') sufficient to obtain the desired spheronisation degree. The temperature is then lowered to allow the microspheres to solidify; the mixing goes on, possibly with less energy, during the solidification stage (for instance for 10'-50'); the process ends with the interruption of the mixing and the recovery of the microspheres.
The whole process normally takes between 15' and 150', preferably between 50' and 100'.
The microspheres can be sieved through a vibrating sieve to reject eventual parti-cles out of the required size standards.
The so obtained microspheres, in particular the ones destined to the oral admini-1 o stration, are advantageously provided with a gastroresistant coating, (preferably non soluble at pH lower than 5.5), such to ensure the delivery of the active princi-ple just when the duodenum is reached, this way protecting it from the gastric pH;
the~application of said coating polymers is performed through spraying according to the prior art, in a fluid bed or in a spraying pan: coating is easy because of the spherical and regular surface of the microspheres. Examples of gastroresistant polymers which can be applied are: hydroxypropylmethylcellulose phthalate (for instance HP-50 or HP-55), hydroxypropylmethylcellulose acetate succinate (Aqoat°), acrylates (for instance Eudragit° L30D) polyvinylacetophthalate (Sure-teric~). To improve the applicability and the stability of the polymeric membranes 2 o formed by these polymers it can be added, mixed to the same coating, plasticizing agents such as for instance, triethylcitrate or dibutylphthalate. Moreover the gliding agents like the talc are helpful to reduce the adhesion among the pellets during the coating process.
The hydrophily of the above mentioned hydrophilic low-melting polymers allow the ' microspheres of the invention to quickly get the enzymes bio-available in the duo-denal environment, once the gastroresistant coating is dissolved.
A further object of the invention are microspheres of pancreatic enzymes with high bio-availability, produced according to the above described process.
The present process allows in fact to obtain new microspheres of pancreatic en-3 o zymes, having the following features: (a) reduced- size, with diameter between 10 pm and 1500 pm, preferably between 100 pm and 800 pm, thus with a high bio-availability of the enzyme once administered; (b) high enzyme title; with high en-zymatic title is meant an enzymatic title of the microsphere (measured in.
unit FIP/mg) equal to or higher than 90%, preferably equal to or higher than 95%, than the title of the solid mixture (enzyme, hydrophilic polymer and excipients in their initial quantities) from which they were produced; said mixture is in the following indicated as "physical mixture of their components". In other words, the activity of the pancreatic enzyme contained in the present microspheres is >_ 90%, preferably 95% of the activity of the native, untreated enzyme.
In case the microspheres include more than one pancreatic enzyme, the above mentioned enzymatic title is to be determined with reference to the activity of the so most thermolabile among them; for instance, in the case of pancreatin (which in-cludes lipase, amylase and protease), the enzyme whose title is measured is 1i-pase.
The microspheres according to the present invention have a high surface regular-ity and a prolonged stability of the enzymatic title in time.
z5 The microspheres obtained according the present invention include: one or more pancreatic enzymes, in weight ratio between 40% and 99%, preferably between 60% and 85%; one or more hydrophilic polymers, in quantity from 1 % to 60%, preferably between 15% and 40%, and excipients pharmaceutically acceptable.
A further object of the invention are pharmaceutical compositions including the 2o above described microspheres (eventually coated with coating polymers) and other excipients suitable for the pharmaceutical use, for example lubricants, gliding agents, coloring agents, diluents, etc. Said compositions can be formulated in forms suitable for the human or animal administration, for instance powders or pellets in sachets to dilute into water when used, suspensions, capsules of hard or 25 soft gelatine, tablets or microtablets.
The present invention offers several advantages: the direct spheronisation process is quick and inexpensive, since it is not necessary to use organic solvents, expen-sive and potentially dangerous if wasted in the environment, nor water, which re-quires long desiccation times and could inactivate the enzymes. Contrary to ali ex-3 o pectations, this process can be efficiently performed even at temperatures higher than the ones of said enzymes denaturation, without reducing the activity in fihe latter. The so produced microspheres have a very reduced diameter, lower than _$-700 Nm on average, thus allowing a high bio-availability. The microspheres' regu-lar surface allows to obtain pharmaceutical coated forms using a smaller quantity of coating polymers: this allows to reduce the quantity of coating agent and the time required for the coating, so reducing the process costs and the enzymes inac-tivation risks. As highlighted in the experimental part, the microspheres have an enzymatic title substantially unchanged as the native enzyme and a high activity persistence in storage condition, so allowing the production of pharmaceutical compositions of pancreatic enzymes with high activity and stability.
The present invention .is now described through the following not limitative exam-.~
z o pies.
EXPERIMENTAL PART
The production techniques of microspheres including pancreatic enzymes used as comparison with the present invention are: application of pancreatin on inert nu-cleus seed(ex. 1 ); extrusion and spheronisation (ex. 2). The process according to 15 the present invention (direct spheronisation) is performed in a fluid bed with rotat-ing disc (ex. 3), or with high-energy granulator-mixer (ex. 4). The enzymatic activ-ity is measured as lipasic activity: this enzyme has been chosen as reference since it is the most labile among the pancreatic enzymes. The activity is deter-mined according to analytical assays of biological type described in the European 2 o and American Pharmacopoeia and are expressed in Unit/mg (Unit F1P or Unit USP
according to the used assay). According to the European Pharmacopoeia 1 mg of pancreatin has to contain not less than 1 U-FIP of proteolitic activity, not less than 15 U-FIP of lipolitic activity and not less than 12 U-FIP of amilolitic activity.
Example 1 (Reference) 2 5 Preparation of pancreatin pellets through po~nrder application on inert nuclei In the basket of a fluid bed of the type Glatt GPCG-1 provided with rotor insertion (rotating disc) are placed 798.0 g of neutral pellets (type "non-pareil seeds", formed by saccharose and maize starch) having sizes between 250 and 350 pm.
The pellets are heated to 23°C by blowing warm air at 28°G.
The entering air 3o speed is 1.m/sec for.the process whole time. Separately the powdered pancreatin is mixed with 2.0% by weight of colloidal silica (Aerosil~ V200) to improve its flow-ability. The entering air temperature in the fluid bed is increased to 54°-C so that _g_ the pellets temperature is about 27-28°C, and 490.0 g of said mixture are applied through a proportioning device Heton Feeder at a rate of 26 g/min, while simulta-neously demineralized water is sprayed through a nozzle with a 0.8 mm hole and a flow rate of about 5-6 g/min. The filtering hoses are shaken for 5 secorids any 12 sec at the beginning of the process. After 25 minutes application it is necessary to shake the hoses for 5 sec any 6 sec. The pellets are dessicated by blowing air at 50°C, so to remove traces of residual water, and finally cooled by 30°C air for 10 minutes. The total time of the process is 120 minutes. This technique involves long process times since large amounts of active principle are brought into the filtering so hoses by the air stream; the size of the microspheres is difficult to control. The theoretical title of the pellets (lipase), calculated by the composition, was 18.27 U-USP/mg. The obtained lipase title was, on the contrary, 8.39 U-USP/mg: This technique involves a loss in the enzymatic activity equal to 54%.
Example 2 (Reference) i5 Preparation of pancreatin pellets through extrusion-saheronisation 660.0 g of pancreatin, 2465.1 g of Avicel° PH101 (microcrystalline cellulose), 165.0 g of Kollidon° K30 (polyvinylpyrrolidone) and 9.9 g of Syloid° 244 (colloidal silica) are mixed in an 18 liters mixing cube at 18 rpm.for 15 minutes. The mixture is fed through a co-rotating double screw extruder TSA EF 26-20. The cochlea of 2 o the feeding hopper is in position III, while the extruder cochlea is rotated at 125 rpm. Simultaneously a solution is fed including demineralized water and isopropyl alcohol in proportion 4:1 w/w by means of a peristaltic pump Watson-Marlow at about 20 g/min. The product is extruded with a 0.4 mm axial die. The total extru-sion time is 102 minutes. Immediately after the extrusion, the product is 25 spheronized with a spheronizer Glatt P-50 with rotating speed of 750 rpm .for 3 minutes. The so obtained pellets are desiccated in thermostatic furnace at 35 °C
for 15 hours. The theoretical title of the pellets, calculated by the composition, was 16.25 U-FIP/mg. The obtained .lipase title was, on the contrary, 0 U-FIP /mg.
It is supposed that the lipase is degraded (100% activity loss) because of the process 3o conditions (overheating of the product and/or presence of water in the extruded mass).
Further reference experiments made by the Applicant, did not highlight any better results: the wet granulation produces pellets with irregular surface requiring too high quantity of gastroresistant coating polymers; the application of pancreatin on pancreatin pellets (in fluid bed with rotating disc Glatt GPCG-1 with insertion Rotor "tangential spray") is a too long process, with frequent stoppage of the filter hoses, s and with difFiculty in controlling the microspheres sizes Example 3 Preparation of pancreatin pellefis through direct s,pheronisation in fluid bed 680.0 g of pancreatin and 320.0 g of PEG400 (polyethylene glycol) are placed in the basket of a fluid bed Glatt GPCG-1 provided with Rotor insertion. The disc is of so the knurled type and revolves at 1200 rpm, while simultaneously air is blown at 70°C at about 1-2 m/sec. The filter hoses are shaken for 5 sec any 6 sec. After 60 minutes spheronisation the entering air temperature is lowered to 20°C
to obtain the hardening of the pellets, while the disc rotation keeps on at 700 rpm. In this stage the shaking of the filters is of 5 sec any 12 sec. After about 30 min cooling s5 the product is unloaded from the basket of the fluid bed. The process total time is 90 minutes. The theoretical title of the pellets, calculated by the composition, was 40.12 U-FIP/mg. The obtained enzymatic title (lipase) was 38.12 U-FIP/mg, with.
an activity loss lower than 5%.
In all test the ponderal yield of pellets having sizes between 150 Nm and 700 Nm 2 o was measured (Table 1 ). With the same percentual compositions, by increasing the disc rotation speed, it was possible to reduce the spheronisation time, whereas the diameter of the microspheres did not change remarkably (Table 2).
Example 4 Precaration of pancreatin pellets through direct spheronisafiion in mixer-granulator 25 717.8 g of pancreatin and 190.8 of PEG4000 (polyethylene glycol) are placed in the tank of an high-energy mixer-granulator zanchetta Rotolab. The blades of the machine are run at 900 rpm and the heating jacket is set at 75°C. After 45 minutes spheronisation the heating is switched .off, the blades speed is lowered to 120 rpm and the jacket is cooled through pipe water flow. After 15 minutes cooling the pel-3 0 lets are unloaded. The process total time is 60 minutes. The theoretical title of the pellets, calculated by the composition, was 65.87 U-FIP/mg. The obtained enzy-matic title (lipase) was 67.80 U-FIP/mg.
Using the described process, with a mixer-granulator Zanchetta Rotolab P-50 spherical pellets are obtained which are afterwards coated with a gastroresistant membrane formed by HP-55, triethylcitrate and talc. The coated' pellets are wrapped up in thermo-sealed sachets (formed by a triple layer of paper, aluminum and polyethylene) and subjected to stability test at 25°C + 60% UR and at 30°C +
60% UR. The stability results of two lots made according to this process, ex pressed in percentage residual lipase activity, are reported in Figure 1: it is to no tice that the microsphere enzymatic activity remains substantially unchanged (fluctuating in a range of 90-110% of the initial value) during the whole test time (6 so months).
In short, the data of the above reported examples show that, while the known pro-cesses (reference examples 1-2) bring to a substantial reduction in the enzymatic activity, the process object of the present invention (examples 3-4) allows to obtain microspheres having very small sizes (<700 pm) and an enzymatic title 95% to 15 over 100% than the native enzyme, thus substantially unchanged; the stability in time of these values is confirmed by the data in figure 1. Said results then highlight the unforeseen efficiency of the process of the present invention and the better performance of the microspheres so obtained. Further tests have been made in the condition of the example 3, changing the hydrophilic low-melting polymer con-e o centration and the disc rotation speed. The table 1 and 2 show the process yield.
The PEG concentration is measured as weight rate of PEG with respect to the starting mixture; the process yield is calculated as weight rate (with respect to the starting mixture) of the microspheres fraction having dimensions included between 150 and 700 pm.
2 s Table 1.
ROTATION SPEED PROCESS YIELD
PEG % RPM WEIGHT % 150-700 M
20 700 48.9 25 700 58.1 30 700 80.6 32 700 91 ~8 Increasing the disc rotation speed to 1200 rpm (table 2) the yield values are not remarkably changed, while it has proved possible to reduce of 10-15% the process total time, to advantage of the enzyme stability.
Table 2.
ROTATION SPEED PROCESS YIELD
PEG % RPM WEIGHT % 150-700 M
20 1200 41.6 25 1200 47.9 30 1200 83.3 32 1200 . . ~ 90.8
Claims (17)
1. Microspheres containing one or more pancreatic enzymes, one or more hydro-philic low melting polymers, and optionally excipients for pharmaceutical use, said microspheres having diameter comprised between 10 µm and 1500 µm and en-zymatic title equal to or higher than 90% of the title of the solid mixture of their components.
2. Microspheres according to claim 1, having diameter comprised between 100 µm and 800 µm and enzymatic title equal to or higher than 95% of the title of the solid mixture of their components.
3. Microspheres according to claims 1-2, where said hydrophilic polymer has melting point between 20°C and 90°C.
4. Microspheres according to claims 1-3, where said hydrophilic polymer has melting point between 30°C and 70°C.
5. Microspheres according to claims 1-4, including between 15% and 40% w/w of said hydrophilic polymer and between 60% and 85% w/w of said pancreatic en-zymes.
6. Microspheres according to claims 1-5, where said hydrophilic polymer is cho-sen among polyethylene glycol, polyoxyethylene, copolymers of polyoxyethylene and polyoxypropylene or their mixtures.
7. A process for the production of the microspheres described in claims 1-6, char-acterized in that a solid mixture formed by one or more pancreatic enzymes;
one or more hydrophilic low-melting polymers and optional excipients, is heated to a temperature equal to or higher than the melting temperature of said hydrophilic low melting polymer, in stirring condition.
one or more hydrophilic low-melting polymers and optional excipients, is heated to a temperature equal to or higher than the melting temperature of said hydrophilic low melting polymer, in stirring condition.
8. A process according to claim 7, including the following stages:
a. loading of a suitable reactor with said solid mixture or its single components in solid state;
b: stirring of the mixture at high-energy conditions and heating of the mixture at a temperature equal to or higher than the melting temperature of said hydrophilic polymer;
c: cooling of the mixture while stirring;
d: recovery of the solidified microspheres.
a. loading of a suitable reactor with said solid mixture or its single components in solid state;
b: stirring of the mixture at high-energy conditions and heating of the mixture at a temperature equal to or higher than the melting temperature of said hydrophilic polymer;
c: cooling of the mixture while stirring;
d: recovery of the solidified microspheres.
9. A process according to claims 7-8, where said hydrophilic polymer has a melt-ing point between 20°C and 90°C.
10. A process according to claims 7-9, where said hydrophilic polymer has a melting point between 30°C and 70°C.
11. A process according to claims 7-10, where said solid mixture includes, be-sides the optional excipients, from 15% to 40% w/w of said hydrophilic polymer and from 60% to 85% w/w of said pancreatic enzymes.
12. A process according to claims 7-11, where said hydrophilic polymer is chosen among polyethylene glycol, polyoxyethylene, copolymers of polyoxethylene and polyoxypropylene or mixtures thereof.
13. A process according to claims 7-12, performed within a high-energy mixer-granulator or in a fluid bed with rotating disc.
14. A process according to claims 7-13, where the obtained microspheres are further coated with a polymeric film.
15. Microspheres obtainable through the process described in claims 7-14.
16. Pharmaceutical compositions comprising the microspheres described in claims 1-6 or 15, optionally coated with a polymeric film, and eventual pharmaceu-tically acceptable excipients.
17. The compositions according to claim 16, in form of powder or pellets, hard or soft gelatine capsules, tablets, microtablets, solutions or suspensions.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2000MI002456A IT1319655B1 (en) | 2000-11-15 | 2000-11-15 | PANCREATIC ENZYME MICROSPHERES WITH HIGH STABILITY AND RELATIVE PREPARATION METHOD. |
| ITMI2000A002456 | 2000-11-15 | ||
| PCT/EP2001/013115 WO2002040045A2 (en) | 2000-11-15 | 2001-11-13 | Microspheres of pancreatic enzymes with high stability |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2428837A1 true CA2428837A1 (en) | 2002-05-23 |
Family
ID=11446110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002428837A Abandoned CA2428837A1 (en) | 2000-11-15 | 2001-11-13 | Microspheres of pancreatic enzymes with high stability |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9259393B2 (en) |
| EP (1) | EP1335706B1 (en) |
| JP (1) | JP4555981B2 (en) |
| KR (1) | KR20030060105A (en) |
| AT (1) | ATE292959T1 (en) |
| AU (1) | AU2002224843A1 (en) |
| CA (1) | CA2428837A1 (en) |
| DE (1) | DE60110106T2 (en) |
| ES (1) | ES2240559T3 (en) |
| IT (1) | IT1319655B1 (en) |
| WO (1) | WO2002040045A2 (en) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6632429B1 (en) | 1999-12-17 | 2003-10-14 | Joan M. Fallon | Methods for treating pervasive development disorders |
| US20070053895A1 (en) * | 2000-08-14 | 2007-03-08 | Fallon Joan M | Method of treating and diagnosing parkinsons disease and related dysautonomic disorders |
| IT1319655B1 (en) | 2000-11-15 | 2003-10-23 | Eurand Int | PANCREATIC ENZYME MICROSPHERES WITH HIGH STABILITY AND RELATIVE PREPARATION METHOD. |
| US8030002B2 (en) * | 2000-11-16 | 2011-10-04 | Curemark Llc | Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions |
| US8100844B2 (en) * | 2002-04-25 | 2012-01-24 | Ultraflex Systems, Inc. | Ambulating ankle and knee joints with bidirectional dampening and assistance using elastomeric restraint |
| EP1729797B1 (en) * | 2004-03-22 | 2008-09-10 | Solvay Pharmaceuticals GmbH | Oral pharmaceutical compositions of lipase-containing products, in particular of pancreatin, containing surfactants |
| US20060198838A1 (en) * | 2004-09-28 | 2006-09-07 | Fallon Joan M | Combination enzyme for cystic fibrosis |
| WO2007014896A1 (en) | 2005-07-29 | 2007-02-08 | Solvay Pharmaceuticals Gmbh | Processes for the manufacture of sterilized pancreatin powder |
| RU2408364C2 (en) * | 2005-08-15 | 2011-01-10 | Зольвай Фармасьютиклз Гмбх | Pancreatine micropellet nuclei to be entero-soluble coated |
| CN101242811B (en) * | 2005-08-15 | 2015-06-17 | 雅培实验室有限公司 | Controlled release pharmaceutical compositions for acid labile drugs |
| US11266607B2 (en) * | 2005-08-15 | 2022-03-08 | AbbVie Pharmaceuticals GmbH | Process for the manufacture and use of pancreatin micropellet cores |
| US9198871B2 (en) | 2005-08-15 | 2015-12-01 | Abbott Products Gmbh | Delayed release pancreatin compositions |
| BRPI0614411A2 (en) * | 2005-08-15 | 2011-03-29 | Solvay Pharm Gmbh | pancreatin micropellet cores suitable for enteric coating |
| DE602006012346D1 (en) * | 2005-08-15 | 2010-04-01 | Solvay Pharm Gmbh | PHARMACEUTICAL COMPOSITIONS WITH CONTROLLED RELEASE FOR SAEELELABILE MEDICINAL PRODUCTS |
| US20080058282A1 (en) | 2005-08-30 | 2008-03-06 | Fallon Joan M | Use of lactulose in the treatment of autism |
| US20070116695A1 (en) * | 2005-09-21 | 2007-05-24 | Fallon Joan M | Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders |
| US10072256B2 (en) | 2006-05-22 | 2018-09-11 | Abbott Products Gmbh | Process for separating and determining the viral load in a pancreatin sample |
| RU2445952C2 (en) * | 2007-02-20 | 2012-03-27 | Юранд Фармасьютикалз Лимитед | Stable compositions of digestive enzymes |
| PT2079445E (en) | 2007-02-20 | 2016-02-29 | Allergan Pharmaceuticals Internat Ltd | Stable digestive enzyme compositions |
| US20090130063A1 (en) * | 2007-11-15 | 2009-05-21 | Solvay Pharmaceuticals Gmbh | Process for separating and determining the viral load in a pancreatin sample |
| WO2009109856A2 (en) | 2008-03-07 | 2009-09-11 | Axcan Pharma Inc. | Method for detecting infectious parvovirus in pharmaceutical preparations |
| US8658163B2 (en) | 2008-03-13 | 2014-02-25 | Curemark Llc | Compositions and use thereof for treating symptoms of preeclampsia |
| US8084025B2 (en) | 2008-04-18 | 2011-12-27 | Curemark Llc | Method for the treatment of the symptoms of drug and alcohol addiction |
| US20090324730A1 (en) * | 2008-06-26 | 2009-12-31 | Fallon Joan M | Methods and compositions for the treatment of symptoms of complex regional pain syndrome |
| US9320780B2 (en) | 2008-06-26 | 2016-04-26 | Curemark Llc | Methods and compositions for the treatment of symptoms of Williams Syndrome |
| PL2318035T3 (en) * | 2008-07-01 | 2019-10-31 | Curemark Llc | Methods and compositions for the treatment of symptoms of neurological and mental health disorders |
| US10776453B2 (en) * | 2008-08-04 | 2020-09-15 | Galenagen, Llc | Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain |
| US20100092447A1 (en) | 2008-10-03 | 2010-04-15 | Fallon Joan M | Methods and compositions for the treatment of symptoms of prion diseases |
| BRPI1007379B8 (en) | 2009-01-06 | 2022-07-19 | Curemark Llc | pharmaceutical compositions for the treatment or prevention of oral infections by e. coli |
| CA2747611C (en) | 2009-01-06 | 2019-09-17 | Curemark Llc | Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces |
| US9056050B2 (en) | 2009-04-13 | 2015-06-16 | Curemark Llc | Enzyme delivery systems and methods of preparation and use |
| WO2011050135A1 (en) | 2009-10-21 | 2011-04-28 | Curemark Llc | Methods and compositions for the prevention and treatment of influenza |
| CA2785860A1 (en) * | 2009-12-29 | 2011-07-28 | Impax Laboratories, Inc. | Gastroretentive solid oral dosage forms with swellable hydrophilic polymer |
| AU2011248293A1 (en) * | 2010-05-03 | 2012-11-15 | Eurand Pharmaceuticals Limited | Micropellet compositions comprising pancreatin containing digestive enzyme mixtures |
| ES2657673T3 (en) | 2010-10-01 | 2018-03-06 | Aptalis Pharma Limited | Enteric coated pancrelipase formulations, low intensity |
| EP2616048A4 (en) * | 2010-11-19 | 2014-04-02 | Curemark Llc | Preparation and use of combination enzyme and gastrointestinal modulator delivery systems |
| GB2503852B (en) | 2011-04-21 | 2018-12-12 | Curemark Llc | Compounds for the treatment of neuropsychiatric disorders |
| RU2602183C2 (en) | 2011-08-08 | 2016-11-10 | Апталис Фарма Лтд. | Method for dissolution testing of solid compositions containing digestive enzymes |
| US10350278B2 (en) | 2012-05-30 | 2019-07-16 | Curemark, Llc | Methods of treating Celiac disease |
| WO2014052875A1 (en) * | 2012-09-27 | 2014-04-03 | Cynvenio Biosystems, Inc. | Stimulus-sensitive microparticles and methods of use |
| JP2016537387A (en) | 2013-08-09 | 2016-12-01 | アラガン ファーマシューティカルズ インターナショナル リミテッド | Digestive enzyme composition suitable for enteral administration |
| CA2947998A1 (en) | 2014-06-19 | 2015-12-23 | Aptalis Pharma Ltd. | Methods for removing viral contaminants from pancreatic extracts |
| EP3215181A1 (en) | 2014-11-05 | 2017-09-13 | Abbott Laboratories GmbH | Processes for producing compositions with improved safety profile comprising pancreatin and compositions suitable for pharmaceutical use |
| CN110075279A (en) * | 2019-04-25 | 2019-08-02 | 淮安麦德森制药有限公司 | Pancreatin microballoon and its production method |
| US11541009B2 (en) | 2020-09-10 | 2023-01-03 | Curemark, Llc | Methods of prophylaxis of coronavirus infection and treatment of coronaviruses |
| CN113046233B (en) * | 2021-03-15 | 2022-07-15 | 中国科学院过程工程研究所 | Microsphere-membrane integrated enzyme reactor and preparation method and application thereof |
Family Cites Families (121)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1342409A (en) | 1970-07-23 | 1974-01-03 | Ciba Geigy Ag | Flowable pancreatin preparation of low microorgan ism content and a process for its manufacture |
| US4237229A (en) | 1975-06-10 | 1980-12-02 | W. R. Grace & Co. | Immobilization of biological material with polyurethane polymers |
| GB1509866A (en) | 1975-06-10 | 1978-05-04 | Johnson & Johnson | Enteric coated digestive enzyme compositions |
| GB1590432A (en) | 1976-07-07 | 1981-06-03 | Novo Industri As | Process for the production of an enzyme granulate and the enzyme granuate thus produced |
| JPS5535031A (en) | 1978-09-04 | 1980-03-11 | Shin Etsu Chem Co Ltd | Enteric coating composition |
| DE2923279B1 (en) * | 1979-06-08 | 1980-11-20 | Kali Chemie Pharma Gmbh | Process for the production of pancreatin pellets |
| JPS5855125B2 (en) | 1980-03-10 | 1983-12-08 | 信越化学工業株式会社 | Enteric coating agent composition for solid drugs |
| JPS5885159A (en) | 1981-11-17 | 1983-05-21 | Furointo Sangyo Kk | Testing device of elution |
| DE3377506D1 (en) | 1982-12-30 | 1988-09-01 | Nordmark Arzneimittel Gmbh | Process for obtaining pancreatin |
| US4447412A (en) | 1983-02-01 | 1984-05-08 | Bilton Gerald L | Enzyme-containing digestive aid compostions |
| US4704295A (en) | 1983-09-19 | 1987-11-03 | Colorcon, Inc. | Enteric film-coating compositions |
| DE3445301A1 (en) | 1984-12-12 | 1986-06-12 | Hoechst Ag, 6230 Frankfurt | PANCREASE ENZYMES AND METHOD FOR THE PRODUCTION THEREOF |
| JP2521504B2 (en) | 1985-12-27 | 1996-08-07 | 昭和電工株式会社 | Enzyme granulation method |
| ATE109659T1 (en) | 1986-03-21 | 1994-08-15 | Eurasiam Lab | MEDICINAL COMPOSITIONS. |
| US4849227A (en) | 1986-03-21 | 1989-07-18 | Eurasiam Laboratories, Inc. | Pharmaceutical compositions |
| GB2189698A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
| IT1205716B (en) | 1987-01-21 | 1989-03-31 | Samil Spa | PROCEDURE FOR THE PREPARATION OF GASTRORESISTANT AND ENTERO-SOLUBLE MICROSPHERES OF DIGESTIVE ENZYME AND PHARAMCEUTIC PREPARATION WITH MICROSPHERES SO PRODUCED |
| DK435687D0 (en) | 1987-08-21 | 1987-08-21 | Novo Industri As | ENZYM containing granules and processes for their preparation |
| JPH0757312B2 (en) * | 1987-12-11 | 1995-06-21 | 昭和電工株式会社 | Binder for granulation |
| JP2598674B2 (en) * | 1988-05-06 | 1997-04-09 | 昭和電工株式会社 | Method for producing water-soluble microcapsules containing enzymes |
| US5733763A (en) | 1988-08-19 | 1998-03-31 | Novo Nordisk A/S | Enzyme granulate formed of an enzyme-containing core and an enzyme-containing shell |
| DK78189D0 (en) | 1989-02-20 | 1989-02-20 | Novo Industri As | ENZYMOUS GRANULATE AND PROCEDURE FOR PREPARING THEREOF |
| DK78089D0 (en) | 1989-02-20 | 1989-02-20 | Novo Industri As | DETERGENTAL GRANULATE AND PROCEDURES FOR PREPARING THEREOF |
| DK306289D0 (en) | 1989-06-21 | 1989-06-21 | Novo Nordisk As | DETERGENT ADDITIVE IN GRANULATE |
| PH30058A (en) | 1989-11-24 | 1996-11-08 | Biochemie Gmbh | Pancreation preparations |
| IT1246350B (en) | 1990-07-11 | 1994-11-17 | Eurand Int | METHOD FOR OBTAINING A RAPID SUSPENSION OF INSOLUBLE DRUGS IN WATER |
| JP3055799B2 (en) * | 1990-11-21 | 2000-06-26 | 塩野義製薬株式会社 | Pancreatin-containing composition |
| RU2096452C1 (en) * | 1990-12-31 | 1997-11-20 | Пайонир Хай-Бред Интернэшнл, Инк. | Method of producing microcapsule from bacteria in fatty acid and a microcapsule containing lyophilized bacterial culture |
| JPH0790565B2 (en) | 1991-08-06 | 1995-10-04 | 株式会社日本製鋼所 | Slide control method and apparatus for resin molding press |
| US5225202A (en) | 1991-09-30 | 1993-07-06 | E. R. Squibb & Sons, Inc. | Enteric coated pharmaceutical compositions |
| WO1993007859A1 (en) | 1991-10-23 | 1993-04-29 | Warner-Lambert Company | Novel pharmaceutical pellets and process for their production |
| SE9200858L (en) | 1992-03-20 | 1993-09-21 | Kabi Pharmacia Ab | Method for producing delayed release pellets |
| US5616483A (en) | 1992-06-11 | 1997-04-01 | Aktiebolaget Astra | Genomic DNA sequences encoding human BSSL/CEL |
| US5260074A (en) | 1992-06-22 | 1993-11-09 | Digestive Care Inc. | Compositions of digestive enzymes and salts of bile acids and process for preparation thereof |
| US5460812A (en) | 1992-06-22 | 1995-10-24 | Digestive Care Inc. | Compositions of digestive enzymes and salts of bile acids and process for preparation thereof |
| US5578304A (en) | 1992-06-22 | 1996-11-26 | Digestive Care Inc. | Compositions of digestive enzymes and salts of bile acids and process for preparation thereof |
| DE4227385A1 (en) * | 1992-08-19 | 1994-02-24 | Kali Chemie Pharma Gmbh | Pancreatin micropellets |
| JP3264027B2 (en) | 1993-02-24 | 2002-03-11 | ソニー株式会社 | Discharge cell and method of manufacturing the same |
| JP2865548B2 (en) * | 1994-03-08 | 1999-03-08 | 澁谷油脂株式会社 | Fluid cleaning powder and method for producing the same |
| US5955448A (en) | 1994-08-19 | 1999-09-21 | Quadrant Holdings Cambridge Limited | Method for stabilization of biological substances during drying and subsequent storage and compositions thereof |
| DE4422433A1 (en) | 1994-06-28 | 1996-01-04 | Cognis Bio Umwelt | Multi-enzyme granules |
| PL179210B1 (en) | 1994-08-05 | 2000-08-31 | Smithkline Beecham Plc | Container for safely holding substances sensitive to moisture |
| US5733575A (en) | 1994-10-07 | 1998-03-31 | Bpsi Holdings, Inc. | Enteric film coating compositions, method of coating therewith, and coated forms |
| ES2236738T3 (en) | 1995-05-31 | 2005-07-16 | Medzyme N.V. | COMPOSITION TO IMPROVE DIGESTIBILITY AND USE OF NUTRIENTS. |
| US6057139A (en) | 1995-06-29 | 2000-05-02 | Mcneil-Ppc, Inc. | Preblend of microcrystalline cellulose and lactase for making tablets |
| JP3510387B2 (en) * | 1995-06-30 | 2004-03-29 | ライオン株式会社 | Process for producing granulated bleach activator, process for producing bleach or detergent containing granulated bleach activator |
| US5665428A (en) * | 1995-10-25 | 1997-09-09 | Macromed, Inc. | Preparation of peptide containing biodegradable microspheres by melt process |
| US5750104A (en) | 1996-05-29 | 1998-05-12 | Digestive Care Inc. | High buffer-containing enteric coating digestive enzyme bile acid compositions and method of treating digestive disorders therewith |
| DE19622131A1 (en) | 1996-06-01 | 1997-12-04 | Solvay Enzymes Gmbh & Co Kg | New enzyme granules |
| CA2257106C (en) | 1996-06-04 | 2002-04-23 | Euro-Celtique, S.A. | Improvements in detection systems and methods for predicting the dissolution curve of a drug from a pharmaceutical dosage form |
| JPH1023888A (en) | 1996-07-10 | 1998-01-27 | Kao Corp | Production of granulated enzyme |
| US8828432B2 (en) | 1996-10-28 | 2014-09-09 | General Mills, Inc. | Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles |
| GB9623205D0 (en) | 1996-11-07 | 1997-01-08 | Eurand Int | Novel pharmaceutical compositions |
| CA2198317C (en) | 1997-02-24 | 2003-01-07 | Mouhsine El Abboudi | Method for preparing pancreatin which contains low amounts of residual organic solvent and product thereof |
| JPH10295374A (en) | 1997-04-30 | 1998-11-10 | Amano Pharmaceut Co Ltd | Production of stable enzyme granules |
| DE19721467A1 (en) * | 1997-05-22 | 1998-11-26 | Basf Ag | Process for the preparation of small-scale preparations of biologically active substances |
| SE9702338D0 (en) | 1997-06-18 | 1997-06-18 | Astra Ab | An analytical method and industrial process including the same |
| ES2137862B1 (en) | 1997-07-31 | 2000-09-16 | Intexim S A | ORAL PHARMACEUTICAL PREPARATION INCLUDING A COMPOUND OF ANTI-ULCER ACTIVITY AND PROCEDURE FOR ITS OBTAINING. |
| JP3611456B2 (en) | 1997-09-30 | 2005-01-19 | 日研化学株式会社 | Theophylline sustained release tablets |
| KR19990072826A (en) * | 1998-02-26 | 1999-09-27 | 우재영 | A process for producing enteric-coated pancreatin granules |
| US7201923B1 (en) | 1998-03-23 | 2007-04-10 | General Mills, Inc. | Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles |
| US20010024660A1 (en) | 1999-09-29 | 2001-09-27 | Ismat Ullah | Enteric coated pharmaceutical composition and method of manufacturing |
| US7122207B2 (en) | 1998-05-22 | 2006-10-17 | Bristol-Myers Squibb Company | High drug load acid labile pharmaceutical composition |
| US6733778B1 (en) | 1999-08-27 | 2004-05-11 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
| JP3071427B2 (en) * | 1998-10-09 | 2000-07-31 | 花王株式会社 | Enzyme particles |
| CN100444830C (en) | 1998-11-02 | 2008-12-24 | 伊兰公司，Plc | Multiparticulate modified release composition |
| EP1640451A1 (en) | 1999-10-01 | 2006-03-29 | Novozymes A/S | Spray dried enzyme product |
| US20010046493A1 (en) | 2000-02-24 | 2001-11-29 | Alex Margolin | Lipase-containing composition and methods of use thereof |
| AU2001254730A1 (en) | 2000-03-24 | 2001-10-03 | Societe Des Produits Nestle S.A. | Nutritional composition comprising hydrolysed protein |
| WO2001074980A2 (en) | 2000-04-03 | 2001-10-11 | Novozymes A/S | Enzyme tablets for cleaning improvement |
| IT1319655B1 (en) | 2000-11-15 | 2003-10-23 | Eurand Int | PANCREATIC ENZYME MICROSPHERES WITH HIGH STABILITY AND RELATIVE PREPARATION METHOD. |
| AR032392A1 (en) | 2001-01-19 | 2003-11-05 | Solvay Pharm Gmbh | ENZYMES MIX, PHARMACEUTICAL PREPARATION AND USE OF PREPARED SAID. |
| AUPR272901A0 (en) | 2001-01-25 | 2001-02-22 | Gainful Plan Limited | Method of preparing biological materials and preparations produced using same |
| EP1279402B1 (en) | 2001-07-26 | 2006-11-29 | Ethypharm | Coated granules of allylamine-or benzylamine-anti-mycotics, process for preparation thereof and orodispersible tablets containing said coated granules |
| JP4187085B2 (en) | 2001-08-24 | 2008-11-26 | 三菱電機株式会社 | Vehicle occupant protection device |
| US20040197321A1 (en) | 2002-03-19 | 2004-10-07 | Tibor Sipos | Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients |
| CN1156308C (en) | 2002-04-19 | 2004-07-07 | 北京世诺医药科技有限公司 | Multi-enzyme complex capsule |
| US20040132826A1 (en) | 2002-10-25 | 2004-07-08 | Collegium Pharmaceutical, Inc. | Modified release compositions of milnacipran |
| KR20050086767A (en) | 2002-11-29 | 2005-08-30 | 프로인트 코포레이션 | Water-based shellac coating material, process for producing the same, coated food obtained with the coating material, process for producing the same, coated medicine, process for producing the same, glazing composition for oily snack, method of glazing, and glazed oily snack |
| CA2419572A1 (en) | 2003-02-18 | 2004-08-18 | Axcan Pharma Inc. | High dosage protease formulation |
| US20040213847A1 (en) | 2003-04-23 | 2004-10-28 | Matharu Amol Singh | Delayed release pharmaceutical compositions containing proton pump inhibitors |
| EP1682168B1 (en) | 2003-10-29 | 2013-05-01 | Eli Lilly And Co. | Non-pancreatic proteases for controlling plasma cholecystokinin (cck) concentration and for treating pain |
| US7670624B2 (en) | 2004-01-29 | 2010-03-02 | Astella Pharma Inc. | Gastrointestinal-specific multiple drug release system |
| EP1729797B1 (en) | 2004-03-22 | 2008-09-10 | Solvay Pharmaceuticals GmbH | Oral pharmaceutical compositions of lipase-containing products, in particular of pancreatin, containing surfactants |
| US20050281876A1 (en) | 2004-06-18 | 2005-12-22 | Shun-Por Li | Solid dosage form for acid-labile active ingredient |
| US20060198838A1 (en) | 2004-09-28 | 2006-09-07 | Fallon Joan M | Combination enzyme for cystic fibrosis |
| JP4908420B2 (en) | 2004-10-14 | 2012-04-04 | アルタス ファーマシューティカルズ インコーポレイテッド | Composition comprising lipase, protease and amylase for treating pancreatic dysfunction |
| US20070025977A1 (en) | 2005-07-21 | 2007-02-01 | Mulberg Andrew E | Method of treating steatorrhea in infants |
| KR101199196B1 (en) | 2005-07-25 | 2012-11-07 | (주)다산메디켐 | Manufacturing method for spheric granule of pancreatin |
| WO2007014896A1 (en) | 2005-07-29 | 2007-02-08 | Solvay Pharmaceuticals Gmbh | Processes for the manufacture of sterilized pancreatin powder |
| US11266607B2 (en) | 2005-08-15 | 2022-03-08 | AbbVie Pharmaceuticals GmbH | Process for the manufacture and use of pancreatin micropellet cores |
| RU2408364C2 (en) | 2005-08-15 | 2011-01-10 | Зольвай Фармасьютиклз Гмбх | Pancreatine micropellet nuclei to be entero-soluble coated |
| CN101242811B (en) | 2005-08-15 | 2015-06-17 | 雅培实验室有限公司 | Controlled release pharmaceutical compositions for acid labile drugs |
| WO2007053619A2 (en) | 2005-11-01 | 2007-05-10 | Bio-Cat, Inc. | A composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrous as well as people suffering from pancreatic lipase insufficiency |
| US20070141151A1 (en) | 2005-12-20 | 2007-06-21 | Silver David I | Lansoprazole orally disintegrating tablets |
| EP1967211A4 (en) | 2005-12-28 | 2009-12-30 | Takeda Pharmaceutical | Method of producing solid preparation disintegrating in the oral cavity |
| CN101370485A (en) | 2006-01-21 | 2009-02-18 | 艾博特股份有限两合公司 | Dosage form and method for the delivery of drugs of abuse |
| RU2442602C2 (en) | 2006-05-26 | 2012-02-20 | Нестек С.А. | The nutritional compositions on the basis of the extract of touti and methods of their application |
| CN101505611B (en) | 2006-08-07 | 2013-03-27 | 诺维信公司 | Enzyme granules for animal feed |
| KR100804096B1 (en) | 2006-08-31 | 2008-02-18 | (주)아모레퍼시픽 | Cosmetic composition for cleansing containing enzyme capsules stabilized in the highly concentrated surfactant system and the process for preparing thereof |
| US20080199448A1 (en) | 2007-02-16 | 2008-08-21 | Ross Mairi R | Enzyme composition for improving food digestion |
| US20090117180A1 (en) | 2007-02-20 | 2009-05-07 | Giovanni Ortenzi | Stable digestive enzyme compositions |
| PT2079445E (en) | 2007-02-20 | 2016-02-29 | Allergan Pharmaceuticals Internat Ltd | Stable digestive enzyme compositions |
| AU2008239737A1 (en) | 2007-04-13 | 2008-10-23 | Beth Israel Deaconess Medical Center, Inc. | Novel nutritional food products for improved digestion and intestinal absorption |
| WO2009109856A2 (en) | 2008-03-07 | 2009-09-11 | Axcan Pharma Inc. | Method for detecting infectious parvovirus in pharmaceutical preparations |
| US8658163B2 (en) | 2008-03-13 | 2014-02-25 | Curemark Llc | Compositions and use thereof for treating symptoms of preeclampsia |
| CN101430279A (en) | 2008-10-27 | 2009-05-13 | 江南大学 | Method for screening catalysis non-aqueous phase system transesterification enzyme by fluorospectrophotometry |
| US8784884B2 (en) | 2009-09-17 | 2014-07-22 | Stephen Perrett | Pancreatic enzyme compositions and methods for treating pancreatitis and pancreatic insufficiency |
| US20110135728A1 (en) | 2009-12-08 | 2011-06-09 | Miller Jennifer L | Gastric retentive pharmaceutical compositions for extended release of polypeptides |
| MX2012010755A (en) | 2010-03-19 | 2013-03-08 | Aptalis Pharma Canada Inc | Gastro-resistant enzyme pharmaceutical compositions. |
| GB201006178D0 (en) | 2010-04-14 | 2010-06-02 | Ayanda As | Composition |
| AR082943A1 (en) | 2010-08-06 | 2013-01-23 | Aptalis Pharma Ltd | PREDIGERATED NUTRITIONAL FORMULA |
| ES2657673T3 (en) | 2010-10-01 | 2018-03-06 | Aptalis Pharma Limited | Enteric coated pancrelipase formulations, low intensity |
| TW201216951A (en) | 2010-10-21 | 2012-05-01 | Aptalis Pharma Ltd | Oral dosing device for administration of medication |
| JP6166714B2 (en) | 2011-03-27 | 2017-07-19 | セルレシン テクノロジーズ， エルエルシー | Cyclodextrin compositions, articles and methods |
| RU2602183C2 (en) | 2011-08-08 | 2016-11-10 | Апталис Фарма Лтд. | Method for dissolution testing of solid compositions containing digestive enzymes |
| WO2014141121A1 (en) | 2013-03-15 | 2014-09-18 | Aptalis Pharma Ltd. | Composition containing digestive enzymes and nutrients suitable for enteral administration |
| RU2686460C2 (en) | 2013-07-22 | 2019-04-26 | Апталис Фарма Лтд. | High potency pancreatin pharmaceutical compositions |
| JP2016537387A (en) | 2013-08-09 | 2016-12-01 | アラガン ファーマシューティカルズ インターナショナル リミテッド | Digestive enzyme composition suitable for enteral administration |
| RU2015155470A (en) | 2013-11-05 | 2017-08-21 | Апталис Фарма Лтд. | HIGH-PERFORMANCE PHARMACEUTICAL PANCREATIN COMPOSITIONS |
| CA2947998A1 (en) | 2014-06-19 | 2015-12-23 | Aptalis Pharma Ltd. | Methods for removing viral contaminants from pancreatic extracts |
-
2000
- 2000-11-15 IT IT2000MI002456A patent/IT1319655B1/en active
-
2001
- 2001-11-13 EP EP01994654A patent/EP1335706B1/en not_active Revoked
- 2001-11-13 JP JP2002542417A patent/JP4555981B2/en not_active Expired - Fee Related
- 2001-11-13 KR KR10-2003-7006513A patent/KR20030060105A/en not_active Application Discontinuation
- 2001-11-13 WO PCT/EP2001/013115 patent/WO2002040045A2/en active IP Right Grant
- 2001-11-13 DE DE60110106T patent/DE60110106T2/en not_active Expired - Lifetime
- 2001-11-13 CA CA002428837A patent/CA2428837A1/en not_active Abandoned
- 2001-11-13 US US10/416,702 patent/US9259393B2/en not_active Expired - Fee Related
- 2001-11-13 AU AU2002224843A patent/AU2002224843A1/en not_active Abandoned
- 2001-11-13 AT AT01994654T patent/ATE292959T1/en not_active IP Right Cessation
- 2001-11-13 ES ES01994654T patent/ES2240559T3/en not_active Expired - Lifetime
-
2015
- 2015-11-30 US US14/953,638 patent/US9884025B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| ATE292959T1 (en) | 2005-04-15 |
| JP4555981B2 (en) | 2010-10-06 |
| US9259393B2 (en) | 2016-02-16 |
| WO2002040045A2 (en) | 2002-05-23 |
| WO2002040045A3 (en) | 2002-10-31 |
| US20160120815A1 (en) | 2016-05-05 |
| KR20030060105A (en) | 2003-07-12 |
| ES2240559T3 (en) | 2005-10-16 |
| EP1335706B1 (en) | 2005-04-13 |
| US9884025B2 (en) | 2018-02-06 |
| AU2002224843A1 (en) | 2002-05-27 |
| IT1319655B1 (en) | 2003-10-23 |
| EP1335706A2 (en) | 2003-08-20 |
| ITMI20002456A1 (en) | 2002-05-15 |
| DE60110106D1 (en) | 2005-05-19 |
| JP2004513645A (en) | 2004-05-13 |
| DE60110106T2 (en) | 2006-03-02 |
| US20040101562A1 (en) | 2004-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1335706B1 (en) | Process fo r the production of microspheres of pancreatic enzymes with high stability | |
| US5160742A (en) | System for delivering an active substance for sustained release | |
| US5750104A (en) | High buffer-containing enteric coating digestive enzyme bile acid compositions and method of treating digestive disorders therewith | |
| EP1187601B1 (en) | Novel preparation and administration form comprising an acid-labile proton pump inhibitor | |
| US20080311192A1 (en) | Enteric-Coated Glucosinolates And Beta-Thioglucosidases | |
| MX2012012794A (en) | Micropellet compositions comprising pancreatin containing digestive enzyme mixtures. | |
| JPH11315032A (en) | Production of enteric coated pancreatin granule | |
| AU2011323059B2 (en) | Process for preparing products comprising stabilised actives and compositions comprising same | |
| US20140127307A1 (en) | Micropellet compositions comprising pancreatin containing digestive enzyme mixture | |
| JPH04283520A (en) | Spherical nuclei and spherical granule | |
| AU2017341350B2 (en) | Formulations of cysteamine and cysteamine derivatives | |
| CN105640896B (en) | The method for preparing the product comprising stabilizing active object and the composition comprising identical active matter | |
| JP6169137B2 (en) | Process for the preparation of stabilized active substance-containing products and compositions containing the same | |
| KR20010067732A (en) | The composition and preparation method of stablized enteric coated nattokinase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |